USP3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15817526	0.45	2/20
SCHEMBL11563775	0.44	2/20
SCHEMBL15817525	0.39	2/20
SCHEMBL24814139	0.67	1/20
SCHEMBL24814111	0.56	1/20
SCHEMBL28733374	0.54	1/20
SCHEMBL24814112	0.52	1/20
SCHEMBL5746178	0.48	1/20
SCHEMBL29505151	0.48	1/20
SCHEMBL6353135	0.48	1/20
SCHEMBL23888889	0.48	1/20
SCHEMBL24025427	0.47	1/20
SCHEMBL14112381	0.47	1/20
SCHEMBL5750800	0.46	1/20
SCHEMBL31638576	0.46	1/20
SCHEMBL4945778	0.46	1/20
SCHEMBL24025429	0.46	1/20
SCHEMBL18547109	0.45	1/20
SCHEMBL3070912	0.45	1/20
SCHEMBL4945586	0.45	1/20

Clinical trials — most relevant to USP3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine	PHASE2/PHASE3	WITHDRAWN
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）	PHASE3	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease	nan	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED
Genetic Studies of Inflammatory Bowel Disease	nan	COMPLETED
Using Mobile Technology to Improve Self-Regulation	nan	COMPLETED
Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries	nan	RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP3 binder may also engage these)

Protein	Name	Similarity
Q91W36	—	0.999	Q91W36 →
Q6DCJ1	—	0.975	Q6DCJ1 →
Q6GNI6	—	0.973	Q6GNI6 →
Q9H0E7	—	0.970	Q9H0E7 →
D2HBJ8	—	0.969	D2HBJ8 →
Q5DU02	—	0.969	Q5DU02 →
A6H8I0	—	0.967	A6H8I0 →
Q5XGZ2	—	0.966	Q5XGZ2 →
Q6NTR6	—	0.964	Q6NTR6 →
Q0V9G5	—	0.964	Q0V9G5 →
P0C8Z3	—	0.963	P0C8Z3 →
A0JM59	—	0.962	A0JM59 →
Q7ZUM8	—	0.962	Q7ZUM8 →
P34547	—	0.961	P34547 →
Q9UPT9	—	0.961	Q9UPT9 →
A5PN09	—	0.961	A5PN09 →
Q8C2S0	—	0.960	Q8C2S0 →
USP20	Ubiquitin carboxyl-terminal hydrolase 20	0.960	landscape →
Q70EL2	—	0.960	Q70EL2 →
Q28CN3	—	0.960	Q28CN3 →
Q8R5K2	—	0.959	Q8R5K2 →
Q8LAM0	—	0.959	Q8LAM0 →
A6NNY8	—	0.958	A6NNY8 →
A7Z056	—	0.958	A7Z056 →
Q8K387	—	0.957	Q8K387 →
Q9VVR1	—	0.957	Q9VVR1 →
Q6P9L4	—	0.956	Q6P9L4 →
Q70CQ1	—	0.956	Q70CQ1 →
Q8CEG8	—	0.955	Q8CEG8 →
B1WBD7	—	0.955	B1WBD7 →